ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Jesse ElliottZemin BaiShu-Ching HsiehShannon E KellyLi ChenBecky SkidmoreSaid YousefCarine ZhengDavid J StewartGeorge A WellsPublished in: PloS one (2020)
Treatment-related deaths were infrequent among ALK-positive NSCLC. PFS may be improved by alectinib and brigatinib relative to other ALK inhibitors; however, the assessment of OS is likely confounded by treatment crossover and should be interpreted with caution.